SLDB Stock Analysis: Solid Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.067m USD | 12M Return: 127.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solid Biosciences Inc. (NASDAQ: SLDB) is a clinical-stage biotechnology company headquartered in Charlestown, Massachusetts, that develops gene therapies for neuromuscular and cardiac diseases, primarily using adeno-associated virus (AAV)-based delivery. The companys lead candidate, SGT-003, is in a Phase 1/2 trial for Duchenne muscular dystrophy (DMD), a rare genetic disorder with limited treatment options. Founded in 2013 and public since its January 2018 IPO, SLDB operates as a small-cap biotech with a pipeline largely weighted toward early-stage, pre-revenue programs.
The pipeline extends beyond SGT-003 with SGT-212 in a Phase 1b trial for Friedreichs ataxia and several preclinical or discovery-stage assets targeting conditions such as catecholaminergic polymorphic ventricular tachycardia and multiple forms of dilated cardiomyopathy. Solid also invests in platform technologies, including capsid libraries, genetic regulators, immunomodulation, manufacturing purity, and dual gene expression cassettes designed to package multiple transgenes into a single vector. Like most clinical-stage gene therapy developers, its value is driven primarily by R&D progress and clinical readouts rather than commercial product sales.
The company maintains a collaboration and license agreement with Ultragenyx Pharmaceutical and holds license agreements with academic institutions including the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A., supporting its discovery and translational research activities. As a small-cap name in the GICS Biotechnology sub-industry, SLDB is a development-stage issuer whose near-term catalysts are tied to clinical trial milestones for its lead programs.
- SGT-003 Duchenne muscular dystrophy interim phase 1/2 data readout
- Cash runway extension likely requires dilutive equity offering
- Competition intensifies from Sarepta and Capricor in DMD gene therapy
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -9.67 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -171.7m > Net Income -191.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (109.8m) vs 12m ago 65.53% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.91%; Δ -0.91% > 0%) |
| Interest Coverage Ratio: -3.20k > 6 (EBIT TTM -191.7m / Interest Expense TTM 60.0k) |
| A: 0.87 (Total Current Assets 396.8m - Total Current Liabilities 30.3m) / Total Assets 422.9m |
| B: -2.40 (Retained Earnings -1.01b / Total Assets 422.9m) |
| C: -0.50 (EBIT TTM -191.7m / Avg Total Assets 383.4m) |
| D: 7.67 (Book Value of Equity 374.1m / Total Liabilities 48.8m) |
| Altman-Z'' = 2.56 = A |
As of July 08, 2026, the stock is trading at USD 11.15 with a total of 1,416,332 shares traded. Over the past week, the price has changed by +17.74%, over one month by +73.95%, over three months by +44.06% and over the past year by +127.09%.
Current recommended Stop Loss: 10.30 (which is 7.6% or 1.3 ATR below the current price).
Solid Biosciences has received a consensus analysts rating of 4.58. Therefore, it is recommended to buy SLDB.
- StrongBuy: 7
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.4 | 55.9% |
P/S = 3.6454
P/B = 2.6814
Revenue TTM = 0.0 USD
EBIT TTM = -191.7m USD
EBITDA TTM = -190.1m USD
Long Term Debt = 18.5m USD (estimated: total debt 20.7m - short term 2.19m)
Short Term Debt = 2.19m USD (from shortTermDebt, last quarter)
Debt = 20.7m USD (from shortLongTermDebtTotal, last quarter) (leases 20.7m already included)
Net Debt = -360.7m USD (calculated: Debt 20.7m - CCE 381.3m)
Enterprise Value = 706.5m USD (1.07b + Debt 20.7m - CCE 381.3m)
Interest Coverage Ratio = -3.20k (Ebit TTM -191.7m / Interest Expense TTM 60.0k)
EV/FCF = -4.09x (Enterprise Value 706.5m / FCF TTM -172.9m)
FCF Yield = -24.47% (FCF TTM -172.9m / Enterprise Value 706.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.62m) / Revenue TTM)
Tobins Q-Ratio = 1.67 (Enterprise Value 706.5m / Total Assets 422.9m)
Interest Expense / Debt = 0.29% (Interest Expense 60.0k / Debt 20.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -151.5m (EBIT -191.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.10 (Total Current Assets 396.8m / Total Current Liabilities 30.3m)
Debt / Equity = 0.06 (Debt 20.7m / totalStockholderEquity, last quarter 374.1m)
Debt / EBITDA = 1.90 (negative EBITDA) (Net Debt -360.7m / EBITDA -190.1m)
Debt / FCF = 2.09 (negative FCF - burning cash) (Net Debt -360.7m / FCF TTM -172.9m)
Total Stockholder Equity = 257.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.02% (Net Income -191.8m / Total Assets 422.9m)
RoE = -74.45% (Net Income TTM -191.8m / Total Stockholder Equity 257.6m)
RoCE = -69.45% (EBIT -191.7m / Capital Employed (Equity 257.6m + L.T.Debt 18.5m))
RoIC = -38.36% (negative operating profit) (NOPAT -151.5m / Invested Capital 394.8m)
WACC = 14.94% (E(1.07b)/V(1.09b) * Re(15.22%) + D(20.7m)/V(1.09b) * Rd(0.29%) * (1-Tc(0.21)))
Discount Rate = 15.22% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 80.66%
[DCF] Fair Price = unknown (Cash Flow -172.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.51 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.46 | Chg30d=+0.98% | Revisions=-50% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.47 | Chg30d=+1.29% | Revisions=-50% | Analysts=13
EPS current Year (2026-12-31): EPS=-1.96 | Chg30d=+2.36% | Revisions=-69% | GrowthEPS=+1.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.96 | Chg30d=-1.34% | Revisions=-53% | GrowthEPS=-0.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -66% (up=7, down=40)